| 1 | Exhaled breath analysis for the early detection of lung canc… (10.2147/lctt.s104205) | Abstract References ORCID | 126.76 | 48 |
| 2 | Radiation-induced esophagitis in lung cancer (10.2147/lctt.s96443) | Abstract References ORCID | 118.48 | 37 |
| 3 | Pro-gastrin-releasing peptide (ProGRP) as a biomarker in sma… (10.2147/lctt.s149516) | Abstract References ORCID | 110.78 | 29 |
| 4 | Prevalence of driver mutations in non-small-cell lung cancer… (10.2147/lctt.s40817) | Abstract References ORCID | 109.68 | 28 |
| 5 | Fatigue in lung cancer patients: symptom burden and manageme… (10.2147/lctt.s85334) | Abstract References ORCID | 108.54 | 27 |
| 6 | <em>EGFR</em> T790M: revealing the secrets of a… (10.2147/lctt.s117944) | Abstract References ORCID | 107.35 | 26 |
| 7 | Psychosocial challenges for patients with advanced lung canc… (10.2147/lctt.s120215) | Abstract References ORCID | 107.35 | 26 |
| 8 | Bevacizumab in the treatment of NSCLC: patient selection and… (10.2147/lctt.s110306) | Abstract References ORCID | 106.12 | 25 |
| 9 | Validation of liquid biopsy: plasma cell-free DNA testing in… (10.2147/lctt.s147841) | Abstract References ORCID | 102.13 | 22 |
| 10 | Lung cancer in women (10.2147/lctt.s37319) | Abstract References ORCID | 100.68 | 21 |
| 11 | Nutrition support and dietary interventions for patients wit… (10.2147/lctt.s85347) | Abstract References ORCID | 100.68 | 21 |
| 12 | miRNA-21 as a novel therapeutic target in lung cancer (10.2147/lctt.s60341) | Abstract References ORCID | 97.58 | 19 |
| 13 | Epiregulin as a therapeutic target in non-small-cell lung ca… (10.2147/lctt.s60427) | Abstract References ORCID | 95.91 | 18 |
| 14 | Circulating tumor cells (CTCs) in lung cancer: current statu… (10.2147/lctt.s6828) | Abstract References ORCID | 94.15 | 17 |
| 15 | <p>Landscape on CT screening for lung cancer in Asia&l… (10.2147/lctt.s192643) | Abstract References ORCID | 88.21 | 14 |
| 16 | Drug resistance in lung cancer (10.2147/lctt.s6861) | Abstract References ORCID | 88.21 | 14 |
| 17 | HSP90 as a novel molecular target in non-small-cell lung can… (10.2147/lctt.s60344) | Abstract References ORCID | 85.96 | 13 |
| 18 | Lung cancer in Brazil: epidemiology and treatment challenges (10.2147/lctt.s93604) | Abstract References ORCID | 85.96 | 13 |
| 19 | Silicosis and lung cancer: current perspectives (10.2147/lctt.s156376) | Abstract References | 85.80 | 51 |
| 20 | Dyspnea in lung cancer patients: a systematic review (10.2147/lctt.s14426) | Abstract References ORCID | 83.55 | 12 |
| 21 | Osimertinib in the treatment of non-small-cell lung cancer:… (10.2147/lctt.s119644) | Abstract References | 81.16 | 41 |
| 22 | New PD-L1 inhibitors in non-small cell lung cancer &ndas… (10.2147/lctt.s113177) | Abstract References ORCID | 80.94 | 11 |
| 23 | Azacitidine and decitabine have different mechanisms of acti… (10.2147/lctt.s11726) | Abstract References ORCID | 80.94 | 11 |
| 24 | Update on biomarkers for the detection of lung cancer (10.2147/lctt.s23424) | Abstract References ORCID | 80.94 | 11 |
| 25 | Single nucleotide polymorphisms as susceptibility, prognosti… (10.2147/lctt.s13256) | Abstract References ORCID | 78.10 | 10 |
| 26 | Spotlight on necitumumab in the treatment of non-small-cell… (10.2147/lctt.s104207) | Abstract References ORCID | 75.00 | 9 |
| 27 | Electromagnetic navigation bronchoscopy: clinical utility in… (10.2147/lctt.s98643) | Abstract References ORCID | 75.00 | 9 |
| 28 | <p>Approaches to Tumor Classification in Pulmonary Sar… (10.2147/lctt.s186779) | Abstract References | 74.57 | 30 |
| 29 | An Update on the Use of Exhaled Breath Analysis for the Earl… (10.2147/lctt.s320493) | Abstract ORCID | 72.36 | 27 |
| 30 | High expression of AKR1C1 is associated with proliferation a… (10.2147/lctt.s90694) | Abstract References ORCID | 71.57 | 8 |
| 31 | Profile of rociletinib and its potential in the treatment of… (10.2147/lctt.s94337) | Abstract References ORCID | 71.57 | 8 |
| 32 | <p>Targeting RET-rearranged non-small-cell lung cancer… (10.2147/lctt.s192830) | Abstract References | 70.75 | 25 |
| 33 | Proton beam therapy in non-small cell lung cancer: state of… (10.2147/lctt.s117647) | Abstract References ORCID | 67.73 | 7 |
| 34 | Comparative effectiveness and safety of <em>nab</em… (10.2147/lctt.s139647) | Abstract References ORCID | 67.73 | 7 |
| 35 | Nimotuzumab, a novel monoclonal antibody to the epidermal gr… (10.2147/lctt.s16440) | Abstract References ORCID | 67.73 | 7 |
| 36 | AXL receptor tyrosine kinase as a therapeutic target in NSCL… (10.2147/lctt.s60438) | Abstract References ORCID | 67.73 | 7 |
| 37 | Role and inhibition of GLI1 protein in cancer (10.2147/lctt.s124483) | Abstract References | 65.05 | 19 |
| 38 | Pretreatment Glasgow prognostic score and prognostic nutriti… (10.2147/lctt.s142880) | Abstract References | 63.94 | 18 |
| 39 | Oligometastatic non-small-cell lung cancer: current treatmen… (10.2147/lctt.s101639) | Abstract References ORCID | 63.38 | 6 |
| 40 | Spotlight on brigatinib and its potential in the treatment o… (10.2147/lctt.s126507) | Abstract References ORCID | 63.38 | 6 |
| 41 | New prognostic biomarkers and therapeutic effect of bevacizu… (10.2147/lctt.s138887) | Abstract References ORCID | 63.38 | 6 |
| 42 | 1-, 3-, and 5-year survival among early-stage lung cancer pa… (10.2147/lctt.s166320) | Abstract References ORCID | 63.38 | 6 |
| 43 | Potential toxicity and safety evaluation of nanomaterials fo… (10.2147/lctt.s23216) | Abstract References ORCID | 63.38 | 6 |
| 44 | MET targeted therapy for lung cancer: clinical development a… (10.2147/lctt.s23423) | Abstract References ORCID | 63.38 | 6 |
| 45 | The voice of postsurgical lung cancer patients regarding sup… (10.2147/lctt.s59703) | Abstract References ORCID | 63.38 | 6 |
| 46 | Docetaxel in the treatment of non-small cell lung carcinoma:… (10.2147/lctt.s6499) | Abstract References ORCID | 63.38 | 6 |
| 47 | Non-small cell to small cell lung cancer on PD-1 inhibitors:… (10.2147/lctt.s173724) | Abstract References | 61.52 | 16 |
| 48 | <p>Outcome of uncommon EGFR mutation positive newly di… (10.2147/lctt.s181406) | Abstract References | 60.21 | 15 |
| 49 | <p>The Current Understanding Of Asbestos-Induced Epige… (10.2147/lctt.s186843) | Abstract References | 60.21 | 15 |
| 50 | Recognizing Prognostic and Predictive Biomarkers in the Trea… (10.2147/lctt.s235102) | Abstract ORCID | 60.21 | 15 |